-
公开(公告)号：US4323568A
公开(公告)日：1982-04-06
申请号：US100741
申请日：1979-12-06
IPC分类号： C07C15/12 , A61K31/13 , C07D207/16 , C07D211/46 , C07D211/60 , C07D211/62 , C07D295/092 , A61K31/135 , A61K31/495 , C07D295/08
CPC分类号： C07D295/088 , C07D207/16 , C07D211/46 , C07D211/60 , C07D211/62 , Y10S514/822 , Y10T428/258
摘要： (Omega-aminoalkoxy)bibenzyls are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.
-
公开(公告)号：US4485258A
公开(公告)日：1984-11-27
申请号：US403119
申请日：1982-07-29
IPC分类号： A61K31/13 , A61K31/135 , A61K31/19 , A61K31/195 , A61K31/445 , A61P7/02 , A61P43/00 , C07C67/00 , C07C213/00 , C07C217/32 , C07C217/84 , C07C219/04 , C07D211/62 , C07D295/08 , C07D295/092 , C07C59/68
CPC分类号： C07D295/088 , C07D211/62 , Y10S514/822
摘要： (3-Aminopropoxy)bibenzyl derivatives are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.
摘要翻译： （3-氨基丙氧基）联苄衍生物被制备并发现可用作药剂，特别是作为血小板聚集的抑制剂。
-
3.发明授权Pharmaceutically active (3-cyclic aminopropoxy)bibenzyls as inhibitors of platelet aggregation 失效药物活性（3-环氨基丙氧基）联苄作为血小板聚集抑制剂
公开(公告)号：US4599419A
公开(公告)日：1986-07-08
申请号：US629061
申请日：1984-07-09
IPC分类号： A61K31/13 , A61K31/135 , A61K31/19 , A61K31/195 , A61K31/445 , A61P7/02 , A61P43/00 , C07C67/00 , C07C213/00 , C07C217/32 , C07C217/84 , C07C219/04 , C07D211/62 , C07D295/08 , C07D295/092 , C07D241/04 , A61K31/505
CPC分类号： C07D295/088 , C07D211/62 , Y10S514/822
摘要： (3-Aminopropoxy)bibenzyl derivatives are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.
-
公开(公告)号：US4220603A
公开(公告)日：1980-09-02
申请号：US943621
申请日：1978-09-19
IPC分类号： C07C15/12 , A61K31/13 , C07D207/16 , C07D211/46 , C07D211/60 , C07D211/62 , C07D295/092 , C07C93/06
CPC分类号： C07D295/088 , C07D207/16 , C07D211/46 , C07D211/60 , C07D211/62 , Y10S514/822 , Y10T428/258
摘要： (Omega-aminoalkoxy)bibenzyls are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.
摘要翻译： （ω-氨基烷氧基）联苄被制备并发现可用作药剂，特别是作为血小板聚集的抑制剂。
-
公开(公告)号：US5618829A
公开(公告)日：1997-04-08
申请号：US186130
申请日：1994-01-25
申请人： Hisao Takayanagi , Yasunori Kitano , Tamaki Yano , Hiroe Umeki , Hiroto Hara
发明人： Hisao Takayanagi , Yasunori Kitano , Tamaki Yano , Hiroe Umeki , Hiroto Hara
IPC分类号： C07C235/78 , C07C235/88 , C07D207/32 , C07D207/335 , C07D209/14 , C07D211/58 , C07D213/75 , C07D295/185 , C07D307/52 , C07D333/20 , A01N43/40 , A61K31/44 , C07D213/60
CPC分类号： C07D207/335 , C07C235/78 , C07C235/88 , C07D209/14 , C07D211/58 , C07D213/75 , C07D295/185 , C07D307/52 , C07D333/20 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2101/14 , C07C2101/18
摘要： A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of the formula ##STR1## wherein R.sup.1 represents a hydrogen atom,R.sup.2 represents --(CH.sub.2).sub.m -Awherein m is an integer of 0 to 3, andA represents pyridyl which is unsubstituted or is substituted by C.sub.1 -C.sub.3 alkyl said alkyl being unsubstituted or substituted by phenyl, and R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently represent a hydrogen atom, a halogen atom, C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or --OR.sup.13 wherein R.sup.13 represents a hydrogen atom or C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or phenyl, or when their adjacent substituents are taken together, they represent C.sub.1 -C.sub.3 oxyalkylene having one or two oxygen atoms;or a pharmaceutically acceptable salt thereof, anda pharmaceutically acceptable carrier therefor.
摘要翻译： 一种药物组合物，其包含药学有效量的下式化合物，其中R 1表示氢原子，R 2表示 - （CH 2）mA，其中m为0-3的整数，A表示未被取代或未取代的吡啶基 被C1-C3烷基取代，所述烷基是未取代的或被苯基取代，R3，R4，R5，R6和R7各自独立地表示氢原子，卤素原子，未被取代或被卤素取代的C1-C5烷基 原子或-OR 13，其中R 13表示氢原子或未被取代或被卤素原子或苯基取代的C1-C5烷基，或当它们相邻的取代基一起时，它们表示具有一个或两个氧原子的C1-C3氧化烯; 或其药学上可接受的盐及其药学上可接受的载体。
-
6.发明申请公开(公告)号：US20170258890A1
公开(公告)日：2017-09-14
申请号：US15498554
申请日：2017-04-27
申请人： John Coleman , Josephine Helena Cox , Arban Domi , Hiroto Hara , Takashi Hironaka , Makoto Inoue , Dagna Skoog Laufer , Angela Grazia Lombardo , Christopher L. Parks , Eddy Sayeed , Maoli Yuan , Xinsheng Zhang
发明人： John Coleman , Josephine Helena Cox , Arban Domi , Hiroto Hara , Takashi Hironaka , Makoto Inoue , Dagna Skoog Laufer , Angela Grazia Lombardo , Christopher L. Parks , Eddy Sayeed , Maoli Yuan , Xinsheng Zhang
IPC分类号： A61K39/21 , C07K14/005 , C12N15/86 , C12N7/00
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/55511 , A61K2039/55555 , A61K2039/57 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/16034 , C12N2740/16134 , C12N2740/16234 , C12N2740/16271 , C12N2740/16334 , C12N2760/18443 , C12N2760/18843 , C12N2760/18871 , C12N2760/20243
摘要： The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.
-
7.发明授权
公开(公告)号：US4339452A
公开(公告)日：1982-07-13
申请号：US218284
申请日：1980-12-19
申请人： Hiroto Hara , Akihiro Narimatsu
发明人： Hiroto Hara , Akihiro Narimatsu
IPC分类号： A61K31/495 , A61P7/02 , C07D213/80 , C07D241/44 , C07D473/08 , C07D473/10 , C07D473/12
CPC分类号： C07D213/80 , C07D241/44 , C07D473/08 , C07D473/10 , C07D473/12
摘要： Caroverine fumarate has an inhibitory effect on platelet aggregation, and exhibits the beneficial effect of increasing coronary blood flow, especially in coronary arteries, and thus is specifically suitable in applications for ischemic heart diseases.
摘要翻译： 富马酸钙维生素对血小板聚集具有抑制作用，具有增加冠状动脉血流的有益效果，特别适用于冠状动脉，因此特别适用于缺血性心脏病。
-
公开(公告)号：US20110162093A1
公开(公告)日：2011-06-30
申请号：US11922278
申请日：2006-06-13
申请人： Yasuji Ueda , Hiroto Hara , Tsugumine Shu , Mamoru Hasegawa
发明人： Yasuji Ueda , Hiroto Hara , Tsugumine Shu , Mamoru Hasegawa
CPC分类号： C12N15/86 , A61K2039/5256 , A61K2039/53 , C07K16/00 , C07K16/1063 , C12N2760/18843
摘要： [Problems to be Solved] The present invention provides methods for producing antibodies and antibody-producing cells.[Means for Solving the Problems] The present invention provides methods for producing antibodies or antibody-producing cells, such methods including the steps of inoculating non-human animals with minus-strand RNA viral vectors carrying nucleic acids which encode foreign polypeptides to be used as antigens, nucleic acids producing the viral vectors, cells into which the vectors or the nucleic acids producing the vectors have been introduced, or lysates of the cells; and collecting the antibodies or antibody-producing cells from the animals. The antibody production can be induced efficiently by the immune activating effect of the minus-strand RNA viral vectors and a high expression of the antigen polypeptides. The antibodies produced by the methods of the present invention can be used in research and development and in the clinical field.
摘要翻译： [待解决的问题]本发明提供了产生抗体和产生抗体的细胞的方法。 解决问题的手段本发明提供了产生抗体或抗体产生细胞的方法，包括以下步骤：将携带编码外源多肽的核酸的负链RNA病毒载体接种在非人动物中，以用作为 产生病毒载体的核酸，产生载体的载体或核酸的细胞或细胞的裂解物; 并从动物中收集抗体或产生抗体的细胞。 可以通过负链RNA病毒载体的免疫激活作用和抗原多肽的高表达来有效诱导抗体产生。 通过本发明的方法产生的抗体可用于研究和开发以及临床领域。
-
公开(公告)号：US5514711A
公开(公告)日：1996-05-07
申请号：US369263
申请日：1995-01-05
申请人： Yasunori Kitano , Hisao Takayanagi , Koichi Sugawara , Hiroto Hara , Hideo Nakamura , Toshiko Oshino
发明人： Yasunori Kitano , Hisao Takayanagi , Koichi Sugawara , Hiroto Hara , Hideo Nakamura , Toshiko Oshino
IPC分类号： A61K31/16 , A61K31/165 , A61K31/255 , A61K31/275 , A61P35/00 , C07C45/45 , C07C45/54 , C07C45/56 , C07C45/71 , C07C47/575 , C07C49/248 , C07C49/835 , C07C49/84 , C07C59/48 , C07C69/73 , C07C69/84 , C07C235/38 , C07C255/36 , C07C255/40 , C07C255/41 , C07C255/42 , C07C255/56 , C07C255/57 , C07C255/58 , C07C317/46 , C07C255/34
CPC分类号： C07C45/45 , C07C255/40 , C07C255/41 , C07C317/46 , C07C45/54 , C07C45/562 , C07C45/71 , C07C47/575 , C07C49/835 , C07C49/84
摘要： Styrene derivatives of the following general formula (I): ##STR1## or pharmaceutically acceptable salts thereof. A pharmaceutical composition useful as anticancer agent, which comprises the above compound as an essential component, is also provided.
摘要翻译： 下列通式（I）的苯乙烯衍生物：其中（I）或其药学上可接受的盐。 还提供了可用作抗癌剂的药物组合物，其包含上述化合物作为必需组分。
-
公开(公告)号：US5032614A
公开(公告)日：1991-07-16
申请号：US524983
申请日：1990-05-18
申请人： Masanori Osakabe , Hiroto Hara , Yoshikuni Tamao , Ryoji Kikumoto
发明人： Masanori Osakabe , Hiroto Hara , Yoshikuni Tamao , Ryoji Kikumoto
IPC分类号： A61K31/135 , A61K31/19 , A61K31/215 , A61K31/22 , A61K31/225 , A61K31/395 , A61K31/397 , A61K31/40 , A61K31/445 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P43/00 , C07C217/18 , C07C217/32 , C07C219/06 , C07D205/04 , C07D295/08
CPC分类号： A61K31/445 , A61K31/135 , A61K31/19 , A61K31/215 , A61K31/22 , A61K31/395 , A61K31/40
摘要： A method of suppressing vasoconstriction in a warm-blooded animal which comprises administering to said warm-blooded animal an effective amount of a serotonin antagonist compound of the formula (I): ##STR1## wherein: R.sup.1 is hydrogen, halo, C.sub.1 -C.sub.5 alkoxy or C.sub.2 -C.sub.6 dialkyl amino;R.sup.2 is hydrogen, halo or C.sub.1 -C.sub.5 alkoxy;R.sup.3 is hydrogen, hydroxy, --O--(CH.sub.2).sub.n --COOH or --O--CO--(CH.sub.2).sub.l --COOH, wherein n is an integer of 1-5, and l is an integer of 1-3;R.sup.4 is ##STR2## wherein R.sup.5 and R.sup.6 are each independently hydrogen or C.sub.1 -C.sub.8 alkyl, and A is C.sub.3 -C.sub.5 alkylene or C.sub.3 -C.sub.5 alkylene substituted with carboxy; andm is an integer of 0-5,or a pharmaceutically acceptable salt thereof. The use of the compound (I) for the preparation of a pharmaceutical formulation useful as a serotonin antagonist is also provided.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.027 秒)